Dominique Velin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dominique Velin has a total of 255 co-authors. Here are the top co-authors by number of shared publications:
Pierre Michetti
Centre Crohn et colite, Clinique la Source-Beaulieu, avenue Jomini 8, 1004 Lausanne
9 shared publicationsDaniel Bachmann
Service of Gastroenterology and Hepatology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
7 shared publicationsCorentin Richard
6 shared publicationsHanifa Bouzourene
UNISciences, University of Lausanne, UniLabs, Lausanne, Switzerland
6 shared publicationsMeriem Messaoudene
6 shared publications- Alexis Nolin-Lapalme
Faculty of medicine, University of Montreal, Montreal, QC, Canada
5 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by BMJ in Gut Science
- Vol. 1 (1) , e000039
Helicobacter pylori infection reduces cancer immunotherapy efficacy through hepatic urea cycle activation and creatine depletion
Background Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy remains limited to a subset of patients. Increasing evidence implicates the gut microbiota in modulating ICI responses. We previously identified Helicobacter pylori infection as a negative predictor of ICI efficacy.Objective Here, we aimed to elucidate the metabolic mechanisms by which H. pylori impairs antitumour immunity and to evaluate creatine supplementation as a potential therapeutic intervention.Design Using murine models of neonatal H. pylori infection and cancer immunotherapy, we conducted targeted plasma metabolomics, hepatic gene and protein expression profiling and isotope tracing to delineate infection-induced metabolic alterations. Functional assays were used to assess the impact of creatine on CD8+ T cell activation in vitro and in vivo, including CRISPR-Cas9-mediated knockdown of the creatine transporter Slc6a8.Results Neonatal H. pylori infection accelerated the hepatic urea cycle, resulting in systemic depletion of creatine and its precursors. Creatine supplementation restored antitumour immunity in infected mice in a CD8+ T cell-dependent manner. Mechanistically, creatine increased the frequency of tumour-specific effector and effector memory CD8+ T cells in tumour-draining lymph nodes and enhanced the population of tumour-infiltrating T cell factor-1⁻ (TCF-1) granzyme B+ effector CD8+ T cells.Conclusion H. pylori drives metabolic reprogramming that undermines ICI efficacy through creatine depletion and CD8+ T cell dysfunction. Creatine supplementation may offer a promising adjuvant approach to overcome H. pylori-associated resistance to cancer immunotherapy.
- 16 October 2026
- Published by BMJ in Gut Science
- Vol. 1 (1) , e000039
Open AccessHelicobacter pylori infection reduces cancer immunotherapy efficacy through hepatic urea cycle activation and creatine depletion
Background Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy remains limited to a subset of patients. Increasing evidence implicates the gut microbiota in modulating ICI responses. We previously identified Helicobacter pylori infection as a negative predictor of ICI efficacy.Objective Here, we aimed to elucidate the metabolic mechanisms by which H. pylori impairs antitumour immunity and to evaluate creatine supplementation as a potential therapeutic intervention.Design Using murine models of neonatal H. pylori infection and cancer immunotherapy, we conducted targeted plasma metabolomics, hepatic gene and protein expression profiling and isotope tracing to delineate infection-induced metabolic alterations. Functional assays were used to assess the impact of creatine on CD8+ T cell activation in vitro and in vivo, including CRISPR-Cas9-mediated knockdown of the creatine transporter Slc6a8.Results Neonatal H. pylori infection accelerated the hepatic urea cycle, resulting in systemic depletion of creatine and its precursors. Creatine supplementation restored antitumour immunity in infected mice in a CD8+ T cell-dependent manner. Mechanistically, creatine increased the frequency of tumour-specific effector and effector memory CD8+ T cells in tumour-draining lymph nodes and enhanced the population of tumour-infiltrating T cell factor-1⁻ (TCF-1) granzyme B+ effector CD8+ T cells.Conclusion H. pylori drives metabolic reprogramming that undermines ICI efficacy through creatine depletion and CD8+ T cell dysfunction. Creatine supplementation may offer a promising adjuvant approach to overcome H. pylori-associated resistance to cancer immunotherapy.
- 19 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (790) , eadr8941
T cell receptor precision editing of regulatory T cells for celiac disease
Celiac disease, a gluten-sensitive enteropathy, demonstrates a strong human leukocyte antigen (HLA) association, with more than 90% of patients carrying the HLA-DQ2.5 allotype. No therapy is available for the condition except for a lifelong gluten-free diet. To address this gap, we explored the therapeutic potential of regulatory T cells (T regs ). By orthotopic replacement of T cell receptors (TCRs) through homology-directed repair, we generated gluten-reactive HLA-DQ2.5–restricted CD4 + engineered (e) T effector cells (T effs ) and eT regs and performed in vivo experiments in HLA-DQ2.5 transgenic mice. Of five validated TCRs, TCRs specific for two immunodominant and deamidated gluten epitopes (DQ2.5-glia-α1a and DQ2.5-glia-α2) were selected for further evaluation. CD4 + eT effs exposed to deamidated gluten through oral gavage colocalized with dendritic and B cells in the Peyer’s patches and gut-draining lymph nodes and specifically migrated to the intestine. The suppressive function of human eT regs correlated with high TCR functional activity. eT regs specific for one epitope suppressed the proliferation and gut migration of CD4 + eT effs specific for the same and the other gluten epitope, demonstrating bystander suppression. The suppression requires an antigen-specific activation of eT regs given that polyclonal T regs failed to suppress CD4 + eT effs . These findings highlight the potential of gluten-reactive eT regs as a therapeutic for celiac disease.
- 19 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (790) , eadr8941
T cell receptor precision editing of regulatory T cells for celiac disease
Celiac disease, a gluten-sensitive enteropathy, demonstrates a strong human leukocyte antigen (HLA) association, with more than 90% of patients carrying the HLA-DQ2.5 allotype. No therapy is available for the condition except for a lifelong gluten-free diet. To address this gap, we explored the therapeutic potential of regulatory T cells (T regs ). By orthotopic replacement of T cell receptors (TCRs) through homology-directed repair, we generated gluten-reactive HLA-DQ2.5–restricted CD4 + engineered (e) T effector cells (T effs ) and eT regs and performed in vivo experiments in HLA-DQ2.5 transgenic mice. Of five validated TCRs, TCRs specific for two immunodominant and deamidated gluten epitopes (DQ2.5-glia-α1a and DQ2.5-glia-α2) were selected for further evaluation. CD4 + eT effs exposed to deamidated gluten through oral gavage colocalized with dendritic and B cells in the Peyer’s patches and gut-draining lymph nodes and specifically migrated to the intestine. The suppressive function of human eT regs correlated with high TCR functional activity. eT regs specific for one epitope suppressed the proliferation and gut migration of CD4 + eT effs specific for the same and the other gluten epitope, demonstrating bystander suppression. The suppression requires an antigen-specific activation of eT regs given that polyclonal T regs failed to suppress CD4 + eT effs . These findings highlight the potential of gluten-reactive eT regs as a therapeutic for celiac disease.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti–PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti–PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti–PD-1 resistance.Significance:The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti–PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial.This article is highlighted in the In This Issue feature, p. 873
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti–PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti–PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti–PD-1 resistance.Significance:The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti–PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial.This article is highlighted in the In This Issue feature, p. 873
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Supplementary Figure from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Supplementary Figure from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti–PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti–PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti–PD-1 resistance.Significance:The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti–PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial.This article is highlighted in the In This Issue feature, p. 873
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti–PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti–PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti–PD-1 resistance.Significance:The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti–PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial.This article is highlighted in the In This Issue feature, p. 873
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Supplementary Figure from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Supplementary Figure from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
- Open Access
- 23 May 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 899161
The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection
Helicobacter pylori infects the gastric mucosa of a large number of humans. Although asymptomatic in the vast majority of cases, H pylori infection can lead to the development of peptic ulcers gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. Using a variety of mechanisms, H pylori locally suppresses the function of the host immune system to establish chronic infection. Systemic immunomodulation has been observed in both clinical and pre-clinical studies, which have demonstrated that H pylori infection is associated with reduced incidence of inflammatory diseases, such as asthma and Crohn’s disease. The introduction of immunotherapies in the arsenal of anti-cancer drugs has revealed a new facet of H pylori-induced immune suppression. In this review, we will describe the intimate interactions between H pylori and its host, and formulate hypothtyeses describing the detrimental impact of H pylori infection on the efficacy of cancer immunotherapies.
- 23 May 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 899161
Open AccessThe Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection
Helicobacter pylori infects the gastric mucosa of a large number of humans. Although asymptomatic in the vast majority of cases, H pylori infection can lead to the development of peptic ulcers gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. Using a variety of mechanisms, H pylori locally suppresses the function of the host immune system to establish chronic infection. Systemic immunomodulation has been observed in both clinical and pre-clinical studies, which have demonstrated that H pylori infection is associated with reduced incidence of inflammatory diseases, such as asthma and Crohn’s disease. The introduction of immunotherapies in the arsenal of anti-cancer drugs has revealed a new facet of H pylori-induced immune suppression. In this review, we will describe the intimate interactions between H pylori and its host, and formulate hypothtyeses describing the detrimental impact of H pylori infection on the efficacy of cancer immunotherapies.
- Open Access
- 29 January 2022
- Published by Wiley in Helicobacter
- Vol. 27 (2) , e12875
GM‐CSF is key in the efficacy of vaccine‐induced reduction of Helicobacter pylori infection
Background: Helicobacter pylori (H. pylori) colonizes the human gastric mucosa with a high worldwide prevalence. Currently, H. pylori is eradicated by the use of antibiotics. However, elevated antibiotic resistance suggests new therapeutic strategies need to be envisioned: one approach being prophylactic vaccination. Pre‐clinical and clinical data show that a urease‐based vaccine is efficient in decreasing H. pylori infection through the mobilization of T helper (Th) cells, especially Th17 cells. Th17 cells produce interleukins such as IL‐22 and IL‐17, among others, and are key players in vaccine efficacy. Recently, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)‐producing Th17 cells have been identified.Aim: This study explores the possibility that GM‐CSF plays a role in the reduction of H. pylori infection following vaccination.Results: We demonstrate that GM‐CSF+ IL‐17+ Th17 cells accumulate in the stomach mucosa of H. pylori infected mice during the vaccine‐induced reduction of H. pylori infection. Secondly, we provide evidence that vaccinated GM‐CSF deficient mice only modestly reduce H. pylori infection. Conversely, we observe that an increase in GM‐CSF availability reduces H. pylori burden in chronically infected mice. Thirdly, we show that GM‐CSF, by acting on gastric epithelial cells, promotes the production of βdefensin3, which exhibits H. pylori bactericidal activities.Conclusion: Taken together, we demonstrate a key role of GM‐CSF, most probably originating from Th17 cells, in the vaccine‐induced reduction of H. pylori infection.
- 29 January 2022
- Published by Wiley in Helicobacter
- Vol. 27 (2) , e12875
Open AccessGM‐CSF is key in the efficacy of vaccine‐induced reduction of Helicobacter pylori infection
Background: Helicobacter pylori (H. pylori) colonizes the human gastric mucosa with a high worldwide prevalence. Currently, H. pylori is eradicated by the use of antibiotics. However, elevated antibiotic resistance suggests new therapeutic strategies need to be envisioned: one approach being prophylactic vaccination. Pre‐clinical and clinical data show that a urease‐based vaccine is efficient in decreasing H. pylori infection through the mobilization of T helper (Th) cells, especially Th17 cells. Th17 cells produce interleukins such as IL‐22 and IL‐17, among others, and are key players in vaccine efficacy. Recently, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)‐producing Th17 cells have been identified.Aim: This study explores the possibility that GM‐CSF plays a role in the reduction of H. pylori infection following vaccination.Results: We demonstrate that GM‐CSF+ IL‐17+ Th17 cells accumulate in the stomach mucosa of H. pylori infected mice during the vaccine‐induced reduction of H. pylori infection. Secondly, we provide evidence that vaccinated GM‐CSF deficient mice only modestly reduce H. pylori infection. Conversely, we observe that an increase in GM‐CSF availability reduces H. pylori burden in chronically infected mice. Thirdly, we show that GM‐CSF, by acting on gastric epithelial cells, promotes the production of βdefensin3, which exhibits H. pylori bactericidal activities.Conclusion: Taken together, we demonstrate a key role of GM‐CSF, most probably originating from Th17 cells, in the vaccine‐induced reduction of H. pylori infection.
- Top Cited PapersOpen Access
- 14 January 2022
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 12 (4) , 1070-1087
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti–PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti–PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti–PD-1 resistance. Significance: The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti–PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial. This article is highlighted in the In This Issue feature, p. 873
- 14 January 2022
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 12 (4) , 1070-1087
Top Cited PapersOpen AccessA Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti–PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti–PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti–PD-1 resistance. Significance: The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti–PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial. This article is highlighted in the In This Issue feature, p. 873
- Open Access
- 16 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (29)
FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure
Foxc2sustains adult lymphatic vascular specialization and coordinates organ-specific lymph flow, gut microbiota, and inflammation.
- 16 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (29)
Open AccessFOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure
Foxc2sustains adult lymphatic vascular specialization and coordinates organ-specific lymph flow, gut microbiota, and inflammation.